Pomerantz LLP has launched an investigation into AstraZeneca PLC (NYSE: AZN) to determine if the company and its executives engaged in securities fraud or other unlawful practices. The probe follows the July 9, 2026 disclosure that the Phase-3 CARDIO-TTransform trial for Wainua, an amyloid cardiomyopathy treatment developed with Ionis Pharmaceuticals, failed to meet its primary endpoint. This negative clinical outcome triggered a sharp market reaction, raising concerns among investors about potential damages from misleading statements or omitted information.

The investigation by Pomerantz LLP expands the legal scrutiny on AstraZeneca, adding to an earlier probe initiated by Schall Law Firm on July 22, 2026. Both firms are examining whether AstraZeneca issued false or misleading statements regarding the efficacy of Wainua prior to the trial results. Investors who purchased AstraZeneca American Depositary Shares (ADS) are advised to contact Pomerantz LLP to discuss their rights and potential remedies in a class action lawsuit.

Market Impact and Trial Details

On July 9, 2026, AstraZeneca announced the failure of the late-stage Phase-3 CARDIO-TTransform trial. The news resulted in an immediate decline in the company’s stock price. On the same day, AstraZeneca’s ADS price fell $10.79 per share, representing a 5.7% drop, to close at $187.49 per ADS.

Investigation Scope

Pomerantz LLP, founded by Abraham L. Pomerantz, is a premier firm specializing in corporate, securities, and antitrust class litigation. The firm is investigating whether AstraZeneca’s officers and/or directors breached fiduciary duties or engaged in corporate misconduct related to the Wainua development pipeline. The firm has offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv.

Investors interested in joining the class action or discussing their claims can contact Danielle Peyton at Pomerantz LLP via email at dpeyton@pomlaw.com or by phone at 646-581-9980, ext. 7980. The firm emphasizes that prior results do not guarantee similar outcomes in legal proceedings.

AstraZeneca Pharma India Limited has secured regulatory approval from the Central Drugs Standard Control Organization (CDSCO) for its oncology drug Enhertu (Trastuzumab Deruxtecan) for an additional indication in India. The approval, received on July 27, 2026, permits the import, sale, and distribution of the drug for the neoadjuvant treatment of adult patients with HER2-positive Stage II or III breast cancer. This development expands the therapeutic options available for early-stage breast cancer patients in the country.

The regulatory clearance specifically covers the use of Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for concentrate for solution for infusion. Under the approved protocol, the drug is indicated for use followed by a taxane, trastuzumab, and pertuzumab (THP). The approval applies to adult patients diagnosed with HER2-positive breast cancer, defined as IHC 3+ or ISH+, at Stage II or Stage III. The company notified the stock exchanges of this development on July 28, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Approval Details

The following table outlines the key parameters of the regulatory clearance granted by the Directorate General of Health Services, Government of India:

Clinical Significance

The neoadjuvant setting refers to treatment administered prior to primary surgical intervention. Therapies in this phase aim to reduce tumor size and improve surgical outcomes. By securing approval for Enhertu in this specific context, AstraZeneca broadens the landscape of targeted oncology therapies available in India. HER2-positive breast cancer is characterized by elevated expression of the human epidermal growth factor receptor 2 protein, making targeted therapies a critical area of development.

Market Implications

The receipt of permission from the CDSCO paves the way for the marketing of Enhertu in India for this additional indication. The commercial launch remains subject to the receipt of related statutory approvals, if any. This expansion aligns with global treatment standards, offering Indian patients access to advanced targeted therapies that address specific biological markers of the disease. The approval strengthens AstraZeneca’s portfolio in the oncology segment, particularly in early-stage breast cancer management.